Skip to main content
OpenTrials
Completed

NCT Number: NCT01370980

Collaborative Seamless Care in Oncology : Measure and Reinforce Safety and Adherence to Oral Cancer Treatment

The purpose of this study is to implement a support interdisciplinary program(oncologists, pharmacists, physicians, nurses, leagues against cancer) of medication adherence to oral oncology treatments. The aim is to ensure continuity of care between professionals,effectiveness of treatment and patient safety.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Cancer Behavior Health Behavior Medication Adherence Neoplasms Patient Acceptance of Health Care Patient Compliance Treatment Adherence and Compliance

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Policlinique Médicale Universitaire and Centre pluridisciplinaire d'oncologie, CHUV

Lausanne, Canton of Vaud, 1010, Switzerland

About this study

80 patients will be included in swiss-romande hospitals and private oncologists and followed by thirty study pharmacies. Each refusal and drop-out will be documented. Follow-up duration is 48 weeks, with a motivational interviewing at least every three months. Patient adherence will be assessed electronically by MEMS (Medication Event Monitoring System).

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • 18 years and older
  • Treated for a cancer with oral medication (letrozol, exemestan,imatinib, sunitinib, nilotinib, everolimus, deferasirox)
  • French speaking

Exclusion criteria

  • None

Treatment and study plan

Primary outcomes

  1. Change in Medication adherence

    Time frame: 3 months, 6 months, 9 months, 12 months

    MEMS data, completed by informations given in motivational interviewing

Secondary outcomes

  1. Program implementation

    Time frame: 1 year

    Evaluating the implementation of the program in pharmacies

  2. Oncologists, nurses, pharmacists and patients satisfaction

    Time frame: 1 year

    By questionnaire and interviews

  3. Effect of Adverse Drug Reaction (ADR) on medication adherence

    Time frame: 1 year

    By MEMS data and motivational interviewing informations

  4. Change in Adverse Drug Reaction (ADR)

    Time frame: 3 months, 6 months, 9 months, 12 months

    To evaluate the frequency and severity of ADR and the pharmacist's contribution to their management. Data from motivational interviewing.

Sponsors and collaborators

Lead sponsor

Center for Primary Care and Public Health (Unisante), University of Lausanne, Switzerland

Other

Collaborators

  • Centre Hospitalier Universitaire Vaudois

Registry information

Official study title

Collaborative and Seamless Care in Oncology : a Study in Primary Care to Measure and Reinforce Safety and Adherence to Oral Cancer Treatment

Important dates

Study start
2010
Primary completion
2011
Study completion
2014
First posted
Jun 10, 2011
Registry last updated
Jul 17, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.